GMGonçalo A. Marcelo

Gonçalo A. Marcelo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gonçalo A. Marcelo has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Elisabete Oliveira

    BIOSCOPE Research Group, LAQV-REQUIMTE, Chemistry Department, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal

    9 shared publications
  • Carlos Lodeiro

    OMICS & Analytical Development and BIOSCOPE Research Group, LAQV REQUIMTE, Chemistry Department, NOVA School of Science and Technology, NOVA FCT, Portugal

    8 shared publications
  • José Luis Capelo

    OMICS & Analytical Development and BIOSCOPE Research Group, LAQV REQUIMTE, Chemistry Department, NOVA School of Science and Technology, NOVA FCT, Portugal

    7 shared publications
  • Joana Galhano

    BIOSCOPE Research Group, LAQV-REQUIMTE, Chemistry Department, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal

    4 shared publications
  • Hugo Miguel Santos

    OMICS & Analytical Development and BIOSCOPE Research Group, LAQV REQUIMTE, Chemistry Department, NOVA School of Science and Technology, NOVA FCT, Portugal

    3 shared publications
  • Julia Lorenzo

    Institut de Biotecnologia i de Biomedicina, Departament de Bioquimica i Biologia Molecular, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain

    3 shared publications

Latest Publications

  • Open Access

    Development of New Targeted Nanotherapy Combined with Magneto-Fluorescent Nanoparticles against Colorectal Cancer

    by Gonçalo A. Marcelo, David Montpeyó, Joana Galhano, Ramón Martínez-Máñez, José Luis Capelo-Martínez, Julia Lorenzo, Carlos Lodeiro, Elisabete Oliveira

    The need for non-invasive therapies capable of conserving drug efficiency and stability while having specific targetability against colorectal cancer (CRC), has made nanoparticles preferable vehicles and principal building blocks for the development of complex and multi-action anti-tumoral approaches. For that purpose, we herein report the production of a combinatory anti-tumoral nanotherapy using the production of a new targeting towards CRC lines. To do so, Magneto-fluorescent NANO3 nanoparticles were used as nanocarriers for a combination of the drugs doxorubicin (DOX) and ofloxacin (OFLO). NANO3 nanoparticles’ surface was modified with two different targeting agents, a newly synthesized (anti-CA IX acetazolamide derivative (AZM-SH)) and a commercially available (anti-epidermal growth factor receptor (EGFR), Cetuximab). The cytotoxicity revealed that only DOX-containing nanosystems showed significant and even competitive cytotoxicity when compared to that of free DOX. Interestingly, surface modification with AZM-SH promoted an increased cellular uptake in the HCT116 cell line, surpassing even those functionalized with Cetuximab. The results show that the new target has high potential to be used as a nanotherapy agent for CRC cells, surpassing commercial targets. As a proof-of-concept, an oral administration form of NANO3 systems was successfully combined with Eudragit® enteric coating and studied under extreme conditions.


  • Open Access

    Magneto-Fluorescent Mesoporous Nanocarriers for the Dual-Delivery of Ofloxacin and Doxorubicin to Tackle Opportunistic Bacterial Infections in Colorectal Cancer

    by Gonçalo A. Marcelo, Joana Galhano, Tiago T. Robalo, Maria Margarida Cruz, María D. Marcos, Ramón Martínez-Máñez, Maria Paula Duarte, José Luis Capelo-Martínez, Carlos Lodeiro, Elisabete Oliveira

    Cancer-related opportunistic bacterial infections are one major barrier for successful clinical therapies, often correlated to the production of genotoxic factors and higher cancer incidence. Although dual anticancer and antimicrobial therapies are a growing therapeutic fashion, they still fall short when it comes to specific delivery and local action in in vivo systems. Nanoparticles are seen as potential therapeutic vectors, be it by means of their intrinsic antibacterial properties and effective delivery capacity, or by means of their repeatedly reported modulation and maneuverability. Herein we report on the production of a biocompatible, antimicrobial magneto-fluorescent nanosystem (NANO3) for the delivery of a dual doxorubicin–ofloxacin formulation against cancer-related bacterial infections. The drug delivery capacity, rendered by its mesoporous silica matrix, is confirmed by the high loading capacity and stimuli-driven release of both drugs, with preference for tumor-like acidic media. The pH-dependent emission of its surface fluorescent SiQDs, provides an insight into NANO3 surface behavior and pore availability, with the SiQDs working as pore gates. Hyperthermia induces heat generation to febrile temperatures, doubling drug release. NANO3-loaded systems demonstrate significant antimicrobial activity, specifically after the application of hyperthermia conditions. NANO3 structure and antimicrobial properties confirm their potential use in a future dual anticancer and antimicrobial therapeutical vector, due to their drug loading capacity and their surface availability for further modification with bioactive, targeting species.


  • Open Access

    Validation of a Standard Luminescence Method for the Fast Determination of the Antimicrobial Activity of Nanoparticles in Escherichia coli

    by Gonçalo A. Marcelo, Joana Galhano, Maria Paula Duarte, José Luis Capelo-Martínez, Carlos Lodeiro, Elisabete Oliveira

    The use of nanoparticles in multiple industries has raised concerned voices about the assessment of their toxicity/antimicrobial activity and the development of standardized handling protocols. Issues emerge during the antimicrobial assaying of multiple cargo, colorimetric, colloidal nanoformulations, as standard protocols often rely on visual evaluations, or optical density (OD) measurements, leading to high variance inhibitory concentrations (MIC). Thus, a fast, luminescence-based assay for the effective assessment of the antimicrobial activity of nanoparticles is herein reported, using the bioluminescence of an in-house E. coli ATCC® 8739TM construct with the pMV306G13 + Lux plasmid (E. coli Lux). The new strain’s sensitivity to ofloxacin as a standard antibiotic was confirmed, and the methodology robustness verified against multiple nanoparticles and colorimetric drugs. The reduction of incubation from 24 to only 8 h, and the sole use of luminescence (LUX490) to accurately determine and distinguish MIC50 and MIC90, are two main advantages of the method. By discarding OD measurements, one can avoid turbidity and color interferences when calculating bacterial growth. This approach is an important tool that contributes to the standardization of methods, reducing samples’ background interference and focusing on luminescence as a direct probe for bacterial metabolic activity, growth and, most importantly, the correct assessment of nanomaterials’ antimicrobial activity.


  • Open Access

    Development of Cyanine 813@Imidazole-Based Doped Supported Devices for Divalent Metal Ions Detection

    by Joana Galhano, Gonçalo A. Marcelo, Hugo M. Santos, José Luis Capelo-Martínez, Carlos Lodeiro, Elisabete Oliveira

    A NIR cyanine@imidazole derivative Cy1 was synthesized and evaluated as a metal ion sensor in solution. Cy1 was shown to be very sensitive to all metal ions tested, presenting a blue shift in the absorption from 668 nm to 633 nm, followed by a change in colour from pale green to blue with Zn2+, Cd2+, Co2+, Ni2+ and Hg2+ ions. Despite the blue shift in the absorption, a decrease at 633 nm (with a colour change from pale green to colourless), as well as a quenching in the emission intensity at 785 nm were observed for Cu2+ ions. The results show the formation of sandwich complexes of two ligands per metal ion with the highest association constant observed for Cu2+ (Log Kass.abs = 14.76 ± 0.09; Log Kass.emis. = 14.79 ± 0.06). The minimal detectable amounts were found to be 31 nM and 37 nM, with a naked eye detection of 2.9 ppm and 2.1 ppm for Hg2+ and Cu2+ ions, respectively. These results prompted us to explore the applicability of Cy1 by its combination with nanomaterials. Thus, Cy1@ doped MNs and Cy1@ doped PMMA nanoparticles were synthesized. Both nanosystems were shown to be very sensitive to Cu2+ ions in water, allowing a naked-eye detection of at least 1 ppm for Cy1@ doped MNs and 7 ppm for Cy1@ doped PMMA. This colourimetric response is an easy and inexpensive way to assess the presence of metals in aqueous media with no need for further instrumentation.


  • Luminescent silicon-based nanocarrier for drug delivery in colorectal cancer cells

    by Gonçalo A. Marcelo, David Montpeyo, Fernando Novio, Daniel Ruiz-Molina, Julia Lorenzo, Elisabete Oliveira


  • Magnetic, fluorescent and hybrid nanoparticles: From synthesis to application in biosystems

    by Gonçalo A. Marcelo, Carlos Lodeiro, José Luis Capelo, Julia Lorenzo, Elisabete Oliveira


  • New dual colorimetric/fluorimetric probes for Hg2+ detection & extraction based on mesoporous SBA-16 nanoparticles containing porphyrin or rhodamine chromophores

    by Gonçalo A. Marcelo, Sónia M.G. Pires, M. Amparo F. Faustino, Mário M.Q. Simões, M.GRaça P.M.S. Neves, Hugo M. Santos, José Luís Capelo, José Paulo Mota, Carlos Lodeiro, Elisabete Oliveira


  • Designing Eu-β-diketonate complexes as a support of ionic liquid crystals (ILCs) with additional luminescent properties

    by Ignacio Sánchez, Cristián Cuerva, Gonçalo Marcelo, Elisabete Oliveira, Hugo M. Santos, José A. Campo, Carlos Lodeiro, Mercedes Cano


  • Open Access

    Toxicological Evaluation of Luminescent Silica Nanoparticles as New Drug Nanocarriers in Different Cancer Cell Lines

    by Gonçalo Marcelo, Jessica Ariana-Machado, Maria Enea, Helena Carmo, Benito Rodríguez-González, José Luis Capelo, Carlos Lodeiro, Elisabete Oliveira

    Luminescent mesoporous silica nanoparticles, CdTeQDs@MNs@PEG1, SiQDs@Isoc@MNs and SiQDs@Isoc@MNs@PEG2, were successfully synthetized and characterized by SEM, TEM, XRD, N2 nitrogen isotherms, 1H NMR, IR, absorption, and emission spectroscopy. Cytotoxic evaluation of these nanoparticles was performed in relevant in vitro cell models, such as human hepatoma HepG2, human brain endothelial (hCMEC/D3), and human epithelial colorectal adenocarcinoma (Caco-2) cell lines. None of the tested nanoparticles showed significant cytotoxicity in any of the three performed assays (MTT/NR/ LDH) compared with the respective solvent and/or coating controls, excepting for CdTeQDs@MNs@PEG1 nanoparticles, where significant toxicity was noticed in hCMEC/D3 cells. The results presented reveal that SiQDs-based mesoporous silica nanoparticles are promising nanoplatforms for cancer treatment, with a pH-responsive drug release profile and the ability to load 80% of doxorubicin.